Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 27:12:731734.
doi: 10.3389/fphar.2021.731734. eCollection 2021.

Musk Tongxin Dripping Pills for treating Ticagrelor in Patients After Percutaneous Coronary Intervention: Echocardiography Combined with Untargeted Metabolomics

Lyu Nan  1 , Lai Peng  1 , Zhao Jinxia  1 , Guo Mengzhe  2 , Liang Jun  1 , Wang Haibo  1 , Geng Houfa  1
Affiliations

Musk Tongxin Dripping Pills for treating Ticagrelor in Patients After Percutaneous Coronary Intervention: Echocardiography Combined with Untargeted Metabolomics

Lyu Nan et al. Front Pharmacol. .

Abstract

Objectives: As current clinical practice guidelines, ticagrelor is the suggested therapeutic scheme to prevent adverse cardiovascular events in acute myocardial infarction (AMI) patients undergoing percutaneous coronary intervention (PCI) treatment. However, this therapeutic strategy still fails, and around 30% patients display inadequate antiplatelet responses. Musk Tongxin Dripping Pill (MTDP) in Chinese hospital was usually considered as the combination with ticagrelor to improve the treatment effect. Unfortunately, the mechanism has not been elucidated. Methods: The untargeted metabolomic method was introduced based on liquid chromatography-high-resolution mass spectrometry (HPLC-HRMS) coupled with STI for the research of the drug combination mechanism between ticagrelor and MTDP. 28 patients with a confirmed diagnosis of AMI were selectively collected, who were then divided into two different dosage regimen groups, and the serum samples were collected for the untargeted metabolomics assay. Then the differential metabolites were associated with blood biochemical indicators. Results: The GLS values in both groups increased after treatment and those in the ticagrelor and MTDP combination group after treatment were higher than those in the ticagrelor group (p < 0.05), suggesting that the combination medication has better therapeutic effect on patients with myocardial infarction. From metabolomics analysis, the species of metabolites changed in two groups before and after treatment. Moreover, 93 differential metabolites changed in the drug combination group compared with the ticagrelor group after treatment (p < 0.05), which mainly related to changes in fatty acid metabolism pathways. Then the differential metabolites were found to be related with blood biochemical indicators, such as lipid, high-density lipoprotein (HDL), and low-density lipoprotein (LDL). Conclusion: This work will provide a possible mechanism of the drug combination interaction between ticagrelor and MTDP from two angles of echocardiography and metabonomics. Several potential metabolic pathways were also found to have a relationship with MTDP, which will provide a new perspective in clinical medication.

Keywords: LC-MS; Musk Tongxin Dripping Pill; echocardiography; ticagrelor; untargeted metabolomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Five main components of MTDP by liquid chromatography–high-resolution mass spectrometry analysis.
FIGURE 2
FIGURE 2
Comparison of GLS values between the ticagrelor group and the MTDP ticagrelor combination group by STI based on echocardiography.
FIGURE 3
FIGURE 3
PCA (A), OPLS-DA (B), differential metabolites (C), and differential metabolic pathway (D) analysis in the ticagrelor group between before and after treatment.
FIGURE 4
FIGURE 4
PCA (A), OPLS-DA (B), differential metabolites (C), and differential metabolic pathway (D) analysis in the ticagrelor MTDP combination group between before and after treatment.
FIGURE 5
FIGURE 5
PCA (A), OPLS-DA (B), differential metabolites (C), and differential metabolic pathway (D) analysis between the ticagrelor group and the ticagrelor MTDP combination group after treatment.
FIGURE 6
FIGURE 6
Correlation analysis between differential metabolites in the ticagrelor MTDP combination group and blood biochemical indexes after treatment.
See this image and copyright information in PMC

References

    1. Basak T., Varshney S., Hamid Z., Ghosh S., Seth S., Sengupta S. (2015a). Identification of Metabolic Markers in Coronary Artery Disease Using an Untargeted LC-MS Based Metabolomic Approach. J. Proteomics 127, 169–177. 10.1016/j.jprot.2015.03.011 - DOI - PubMed
    1. Basak T., Varshney S., Akhtar S., Sengupta S. (2015b). Understanding Different Facets of Cardiovascular Diseases Based on Model Systems to Human Studies: A Proteomic and Metabolomic Perspective. J. Proteomics 127, 50–60. 10.1016/j.jprot.2015.04.027 - DOI - PubMed
    1. Blais C., Rochette L., Ouellet S., Huynh T. (2020). Complex Evolution of Epidemiology of Vascular Diseases, Including Increased Disease Burden: From 2000 to 2015. Can. J. Cardiol. 36, 740–746. 10.1016/j.cjca.2019.10.021 - DOI - PubMed
    1. Chen X., Liu L., Palacios G., Gao J., Zhang N., Li G., et al. (2010). Plasma Metabolomics Reveals Biomarkers of the Atherosclerosis. J. Sep. Sci. 33, 2776–2783. 10.1002/jssc.201000395 - DOI - PubMed
    1. Cui S., Li K., Ang L., Liu J., Cui L., Song X., et al. (2017). Plasma Phospholipids and Sphingolipids Identify Stent Restenosis after Percutaneous Coronary Intervention. JACC Cardiovasc. Interv. 10, 1307–1316. 10.1016/j.jcin.2017.04.007 - DOI - PubMed